Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
47 Cards in this Set
- Front
- Back
Nurse Practice Acts |
Legal boundaries of nursing practice within each state |
|
American Nurses Association |
Agency sets the legal regulations for nursing licensure |
|
Ethics affect nursing |
To respect the rights, dignity, and wishes of the patient |
|
Malfeasance |
Giving correct drug, but wrong route that results in patients death |
|
Nonfeasance |
Omission; omitting a drug dose that results in patients death |
|
Misfeasance |
Negligence; giving the wrong drug or dose that results in patients death |
|
Student nurse’s role compared to licensed nurse’s role in medication administration |
Student nurses are held under the same standards as a licensed nurse |
|
Purpose of the Pure Food & Drug Act of 1906 |
Prevented marketing of altered drugs; required labeling to eliminate false/misleading claims |
|
Purpose of the FDA |
Federal agency responsible for the regulation and enforcement of drug evaluation and distribution policies |
|
Purpose of the Controlled Substances Act of 1970 |
Designed to remedy the escalating problem of drug abuse, including several provisions |
|
3 Nursing interventions to utilize when administering controlled substances |
-Keep special controlled-substance record required info -Countersign all discarded/wasted meds -Ensure that documentation and drugs match *double locked *requires 2 signatures *counted every shift *count every time open |
|
Pregnancy Category A |
preg. women studies= no fetal risk in 1st trimester and no risk evident in later trimesters (No harm) |
|
Pregnancy Category B |
Animal studies= no risk to fetus, no studies in preg. women OR AS= adverse effect on fetus, preg. women studies= no fetal risk in 1st trimester and no risk evident in later trimester |
|
Pregnancy Category C |
Animal studies= adverse effect on fetus, no studies in preg. women; drug benefits in preg. women acceptable despite risk OR No studies in animals or preg. women |
|
Pregnancy Category D |
Evidence of fetal risk but drug benefits in preg. women acceptable despite risks |
|
Pregnancy Category X |
Fetal abnormalities or adverse reaction; fetal risks reports. Risk outweighs benefits in preg. women (Do Not Give!!) |
|
Purpose of 2003: Health Insurance Portability & Accountability Act (HIPAA) |
Sets the standards for privacy of individuals health information. *Ability to read your medical records. |
|
Pharmaceutics |
Dissolution of the drug (Break down so body can use. Oral route- liquid/pill) |
|
Pharmacodynamics |
How the drug affects the body (What it does to the body) |
|
Pharmacogenetics |
Scientific discipline studying how the effect of a drug action varies from a predictable drug response because of genetic factors of hereditary influences. (Hereditary/ genetics med combined) *body can affect medicine |
|
Pharmacokinetics |
Process of drug movement to achieve drug action. (How the body acts on the drugs and how it’s absorbed and distributed) |
|
Pharmacology |
Study of drug action (Study of biological effects of chemicals) |
|
What happens in the Pharmaceutic Phase of Drug Action? |
1st phase of drug action. In GI tract, drugs need to be in solution so they can be absorbed. A drug in solid form must be disintegrated into small particles to dissolve into liquid so it can cross the biological membrane. |
|
How can EC (enteric coated) or SR (sustained release) affect the pharmaceutic phase? |
Disintegration of ec tablets & sr capsules occur in the small intestines. |
|
Organ responsible for metabolism? |
Liver |
|
Organ responsible for excretion? |
Kidneys |
|
Protein affect distribution? |
Portion of drug that’s bound is inactive because it’s not available to receptors, and portion that is inbound remains free, active drug. |
|
How patients age affect distribution? |
Body fat increases and total body water decreases |
|
First pass effect |
Process in which drug passes to liver first, where metabolized to an inactive form or a drug metabolite |
|
Serum half-life |
Time it takes for one half or drug concentrated to be eliminated from the body |
|
Nonspecific drug receptor |
Drugs that affect various sites and have properties of nonspecifity (Works on tissues) |
|
Onset of action |
First set of impact of drug |
|
Peak |
Best relief time |
|
Duration |
How long you have relief |
|
Trough |
Bottom no more relief |
|
Efficacy |
How much we can get out of med “best effect” |
|
Receptor |
Protein in nature found on cell membranes to enhance drug action. (Pain receptor- sites are open, med goes right to pain site and pain receptors close) |
|
Agonist |
Drugs that produce a response |
|
Antagonist |
Drugs that block a response |
|
Nonselective Drug Receptor |
Drugs that affect various receptors |
|
Bioavailability |
Subcategory of absorption percentage of administered drugs dose that reaches systemic circulation. (Protein bound drug) |
|
Absorption |
First step of Pharmokinetics drug is absorbed in GI tract |
|
Distribution |
Second step Pharmokinetics Drug binds to plasma protein and gets transported |
|
Metabolism |
Third step of Pharmokinetics Actioned in the liver Medication converges from a readily lipid soluble into a polar, watery drug |
|
Excreation |
Fourth step of Pharmokinetics Actioned in kidney Medication leaves the body |
|
EC (enteric coated) |
Outer coating that prevents medication from dissolving in the gastric environment |
|
SR (sustained release) |
Outer coating that allows medication to release at a predetermined rate |